Engineering Agonism: A New Frontier in GPCR Antibody Discovery
- Unlocking state-specific GPCR conformations to move beyond binding-only generative models
- Leveraging antibody agonists to precisely tune signaling bias in Class B GPCRs
- Integrating epitope selection with full-molecule engineering for PK, delivery, and developability